The biotech company is looking for multiple successes in the coming years.

AXS-12 reduced the frequency of cataplexy attacks per week compared with placebo (P =.017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with ...

The "Narcolepsy Treatment Market - Global Forecast 2025-2032" report has been added to ResearchAndMarkets.com's offering. Senior leaders in the narcolepsy treatment market face an industry defined by ...

Narcolepsy with cataplexy, now known as type 1 narcolepsy, is a chronic neurological disorder that affects a person’s sleep-wake cycle and involves muscle weakness. The condition can cause a person to ...

Axsome Therapeutics said U.S. health regulators have supported the company's application for its narcolepsy treatment. The biopharmaceutical company said Wednesday that it was provided with formal pre ...

DUBLIN--(BUSINESS WIRE)-- Alkermes plc (ALKS) (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to alixorexton for the ...

A new Northwestern Medicine study has demonstrated a new way to treat narcolepsy-related nightmares. The scientists combined cognitive behavioral therapy (CBT) and lucid dreaming to help patients in a ...

Recently, Alkermes refocused on neuroscience, and now it’s dealing with stabilizing revenues from core products like Lybalvi, Vivitrol, Aristada, and Vumerity. However, the main growth driver going ...

Please provide your email address to receive an email when new articles are posted on . Patients with narcolepsy have increased cardiovascular risks, according to researchers.. Participants who ...

Alkermes Plc (NASDAQ:ALKS) is one of the best breakout stocks to invest in. On November 12, Alkermes Plc (NASDAQ:ALKS) delivered positive topline clinical trial data for its narcolepsy treatment, ...